MARKET NEWS

Caris Life Sciences Receives FDA Breakthrough Device Designation
Merus Announces First Patient Treated in Phase 1 Clinical Trial for Advanced Solid Tumors
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program
Octapharma Study Demonstrates Cutaquig Efficacy & Safety
Merck Announces Results from Phase 2 Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Hovione can manufacture drug substance all the way to commercial supplies and perform formulation development and production of early clinical supplies, as well as clinical supplies manufacturing for drug products. With blending, granulation, dry granulation, milling, tableting, film coating, and encapsulation equipment, we can supply few grams batches, for formulation evaluation, to Proof-of-Concept (POC) clinical batches. Click here for more.

  EXCLUSIVE ONLINE CONTENT

HOOKIPA Achieves Research Milestone in Collaboration & License Agreement With Gilead

HOOKIPA Achieves Research Milestone in Collaboration & License Agreement With Gilead

HOOKIPA Pharma Inc. recently announced it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. for development of a therapeutic hepatitis B virus (HBV) vaccine.

RedHill Biopharma Submits NDA for for H. Pylori Infection Drug

RedHill Biopharma Submits NDA for for H. Pylori Infection Drug

RedHill Biopharma Ltd. recently announced that, following a positive pre-NDA meeting held recently with the US FDA, it has submitted a New Drug Application (NDA) to the FDA for Talicia (RHB-105) for the treatment of H. pylori infection.

Akcea & Ionis Announce European Union Drug Approval for Ultra-Rare Disease

Akcea & Ionis Announce European Union Drug Approval for Ultra-Rare Disease

Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced that WAYLIVRA has received conditional marketing authorization from the EC as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride-lowering therapy has been inadequate.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 22 – Nasal Drug Delivery
May 29 – Lyophilization Manufacturing